First COVID-19 Trial Success For Roche’s Actemra, But No Sign It Saves Lives
Trial Focused On Hispanic, Black And Native Americans
Executive Summary
A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.
You may also be interested in...
Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.
Clinical Trial Diversity: We Must ‘Turn This Moment Into A Movement’
Pfizer and Genentech execs describe steps they’ve taken to increase diversity in clinical trials from moving trial sites into new neighborhoods to modifying protocols and holding others accountable for diversity.
Coronavirus Update: South Korean Nod For AZ/Oxford Vaccine, Actemra Progesses In Japan
South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.